JOURNAL ARTICLE

What to Know About Trump's New Executive Order on Psychedelic Drugs.

  • Published In: Time.com, 2026. P. N.PAG 1 of 3

  • Database: Academic Search Ultimate 2 of 3

  • Authored By: Greenwood, Veronique 3 of 3

Abstract

The article focuses on a recent executive order signed by President Donald Trump to expedite the development and approval of certain psychedelic drugs as medical treatments. The order directs the Food and Drug Administration (FDA) to give accelerated consideration to qualifying psychedelics and allocates $50 million from the Department of Health and Human Services to match state investments in psychedelic research for mental health conditions. Psychedelics such as LSD, MDMA (3,4-methylenedioxymethamphetamine), psilocybin, and ibogaine are federally banned but have shown potential in treating conditions like treatment-resistant depression and PTSD. The order signals a shift in federal attitudes toward psychedelics, although experts caution against rushing approvals without sufficient evidence.

Additional Information

  • Source:Time.com. 2026/04, pN.PAG
  • Document Type:Article
  • Subject Area:Law
  • Publication Date:2026
  • ISSN:2476-2679
  • Accession Number:193231706
  • Copyright Statement:Copyright of Time.com is the property of TIME USA, LLC and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Looking to go deeper into this topic? Look for more articles on EBSCOhost.